EP
COGT icon

Essential Partners’s Cogent Biosciences COGT Stock Holding History

Essential Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.58K Hold
197
– – ﹤0.01% 1378
2025
Q4 		$7K Buy
197
+8
+4% +$225 ﹤0.01% 1298
2025
Q3 		$2.71K Buy
189
+45
+31% +$533 ﹤0.01% 1686
2025
Q2 		$1.03K Buy
+144
New +$798 ﹤0.01% 1502

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Essential Partners's COGT Position: Q1 2026 in Review

Essential Partners held its Cogent Biosciences (COGT) position steady in Q1 2026 at 197 shares worth $7.58K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

Essential Partners first reported a position in COGT in Q2 2025 and has held it in 4 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Essential Partners held 197 shares of Cogent Biosciences worth $7.58K as of Q1 2026.
  • Essential Partners left its Cogent Biosciences share count unchanged in Q1 2026.
  • Cogent Biosciences made up ﹤0.01% of Essential Partners's portfolio in Q1 2026, its #1378 holding.
  • Essential Partners first reported a position in Cogent Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Essential Partners's 13F filing for Q1 2026, filed 21 May 2026.